We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 1,287% above its sector, the market expects faster growth.
Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related merchandise. The company's operations are divided into its New Drug Research and Development segment and its Agricultural Products Cultivation segment. Its advanced therapeutic candidate, ON101, is currently undergoing Phase III clinical trials for the treatment of chronic diabetic foot ulcers. Additionally, OB318, an experimental anti-cancer drug, is progressing through Phase I clinical evaluation. The company's development pipeline further includes FB704A, which has successfully concluded its Phase I clinical trial for addressing rheumatoid arthritis and systemic sclerosis. Furthermore, FB825 is currently in Phase II clinical trials, targeting conditions like atopic dermatitis, various allergic diseases, and asthma. In its earlier stages, FB918, a human monoclonal antibody aimed at allergic asthma, is undergoing pre-clinical development. Beyond its pharmaceutical endeavors, Oneness Biotech also oversees agricultural cultivation and trading activities, encompassing the distribution of farm produce. The company was established and began operations in 2008.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 4743.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
